Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06481176 · ClinicalTrials.gov registry record · NA
Blood Changes After Exercise in Restless Legs Syndrome
A NA study of Restless Legs Syndrome, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06481176: Recruiting NA study of Restless Legs Syndrome, sponsored by Stanford University.
NCT06481176 is a NA study of Restless Legs Syndrome that is actively recruiting participants, run by Stanford University. The registered enrollment target is 30 participants, below the 94-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06481176, a NA study of Restless Legs Syndrome, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn how exercise changes molecules in the blood in people with restless legs syndrome (RLS) to better understand the cause(s) of RLS. The main questions the investigators aim to answer are: How does long-term exercise change proteins in the blood? How does a single exercise session change proteins in the blood? The investigators will compare long-term exercise to no exercise to see if the changes in proteins are specific to exercise. Participants will complete an exercise test and provide blood samples before and after the exercise test. Participants will be randomized (like the flip of a coin) in to either the exercise or no-exercise group for 12 weeks and then complete the exercise test and blood samples again at the end.
Primary Outcome
Participants will provide blood samples that will be used to measure proteins in the blood with an aptamer-based multiplexed platform of 11,000+ proteins. Two samples will be collected at the baseline testing session (before the 12-week study period); one right before and one right after the cardiorespiratory fitness test.
Conditions Studied
Interventions
- BEHAVIORAL 12-Week RLS Exercise Program
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT06481176 shows while recruiting
NCT06481176 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 94-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Restless Legs Syndrome appearing as the primary indexed condition, and to 1 intervention - of which 12-Week RLS Exercise Program is the first listed.
NCT06481176 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06481176 about?
NCT06481176 is a clinical study titled "Blood Changes After Exercise in Restless Legs Syndrome". The goal of this clinical trial is to learn how exercise changes molecules in the blood in people with restless legs syndrome (RLS) to better understand the cause(s) of RLS. The main questions the investigators aim to answer are: How does long-term exercise change proteins in the blood? How does a...
What is the current status of trial NCT06481176?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-10-21. Estimated completion is 2026-12.
What conditions does trial NCT06481176 study?
This clinical trial studies the following conditions: Restless Legs Syndrome.
What interventions are being tested in trial NCT06481176?
The interventions under investigation include: 12-Week RLS Exercise Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT06481176?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06481176 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Legs Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06481176's enrollment target sits among peer trials
30 10th of 14 higher than 5 of 14 other Restless Legs Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Restless Legs Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Response to an Investigational Device in Patients With Restless Legs Syndrome
ACTIVE NOT RECRUITING · NA
-
Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome During Opioid Medication Reduction
COMPLETED · NA
-
A Study on the Use of the MMF07 Foot Massager and Heat Therapy Treatments for Restless Leg Syndrome
COMPLETED · NA
-
Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study)
COMPLETED · NA
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI